In this episode, we speak to Dr. Nikolai Naoumov, MD, PhD, FRCP, FRCPAth, FAASLD (Adviser for Clinical Research and Drug Development in Liver Diseases at Novartis, and physician-scientist and specialist in liver diseases).
Episode 4 with Dr. Nikolai Naoumov - Dialogues on AI Digital Pathology.
Introduction of Dr. Nikolai Naoumov
Dr. Nikolai Naoumov,Ph.D.
Development in Liver Diseases at Novartis, and physician-scientist and specialist in liver diseases.
Dr Nikolai Naoumov is an Adviser for Clinical Research and Drug Development in Liver Diseases at Novartis. Additionally, Nikolai has been an adviser for research organizations, pharma companies, the Foundations for Liver Research in the UK and in Switzerland.
Nikolai is a physician-scientist with a professional career combining academic research, clinical care and drug development – all focused on liver diseases. He is a Fellow of the Royal College of Physicians (London) and also the Royal College of Pathologists (UK), and has led research teams at King’s College Liver Unit and subsequently as Professor of Hepatology at University College London.
▲ A picture of Nikolai Naoumov, Ph.D.
Nikolai’s experience at the Novartis headquarters in Basel, Switzerland, stems from all stages of drug development, and leadership of global cross-functional teams and programs. He set-up and led the Therapeutic Area Hepatology with a broad portfolio in non-viral liver diseases.
With his current work focusing on digital pathology with AI assessment of liver biopsies, NASH combination therapies, HBV cure and liver fibrosis, Nikolai is here to talk about the impact of AI digital pathology in drug development efforts for NASH.
大咖对话第2期（音频）：David Kleiner博士和Dean Tai博士-AI数字病理学的对话
杭州筹图科技有限公司 浙ICP备15025848号 浙公网安备 33010802004660号